439 Significantly Higher Pathologic Complete Response Rate with Weekly Compared with Three-weekly Paclitaxel and Carboplatin Plus Trastuzumab Neoadjuvant Therapy – Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 48; p. S175
Main Authors Shao, Z.M, Chen, C.M, Zhou, Y, Chen, S, Hou, Y.F, Liu, G.Y, Di, G.H, Lu, J.S, Wu, J, Shen, Z.Z
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.03.2012
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(12)70505-1